The sildenafil NO → cGMP cascade can be represented as a sequence of linked PD transformations: nitric oxide (NO) synthesis and release establish an upstream signal, NO diffuses to soluble guanylate cyclase (sGC), sGC converts that signal into catalytic activity, and GTP is converted into the second messenger cGMP. cGMP then interacts with downstream signaling machinery, while phosphodiesterase type 5 (PDE5) provides a major route for cGMP hydrolysis. Sildenafil inhibits PDE5, changing the balance between cGMP formation and degradation and therefore altering the persistence and geometry of the intracellular second-messenger signal. The resulting modeled smooth-muscle relaxation can be represented as a concentration–effect relationship whose position, slope, and upper region depend on pathway sensitivity and signal coupling. This framework describes signal transformation across linked PD stages rather than clinical vasodilation or therapeutic outcomes. Differences between sildenafil and Viagra can therefore be discussed in terms of the active molecular entity and its pharmacodynamic representation, without converting pathway geometry into clinical guidance. The key construct is a connected signaling system rather than an isolated drug effect.
NO signaling represents the upstream generation and propagation of a gaseous messenger that initiates the downstream cGMP pathway. Enzymatic NO synthesis converts suitable substrates into NO, after which the molecule is released from its generating cellular environment and diffuses across short biological distances. Because NO is highly diffusible and transient, its signaling geometry depends on the rate and location of synthesis, release dynamics, local diffusion, and removal or reaction processes. These determinants establish the concentration and temporal profile of NO encountered by soluble guanylate cyclase. Greater or more sustained local NO availability can produce a different sGC activation profile from a brief or spatially restricted NO signal. Thus, upstream variability can be propagated into downstream cGMP formation without requiring any change in the downstream molecular machinery itself. In a mechanistic PD comparison, NO signaling is therefore treated as an input domain that shapes the initial amplitude, duration, and spatial geometry of pathway activation. The relevant distinction is signal availability and propagation, not a clinical response. Changes at this stage can alter every subsequent transformation because sGC receives its activating input directly from NO.
Soluble guanylate cyclase, or sGC, converts the NO signal into enzymatic activity capable of generating cGMP. NO binds to the heme-containing regulatory region of sGC, producing a conformational change that substantially increases the catalytic activity of the enzyme. This activation changes the rate at which sGC converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). The resulting cGMP production profile is therefore determined by both the characteristics of the incoming NO signal and the responsiveness of the sGC system. If NO exposure is brief, sGC activation can be correspondingly transient; if the upstream signal persists, catalytic activity can remain engaged for a longer interval. Differences in sGC abundance, molecular responsiveness, activation kinetics, or coupling efficiency can shift the relationship between NO input and cGMP output. Mechanistically, this creates an intermediate transformation layer between NO availability and second-messenger formation. The geometry of cGMP generation can therefore differ even when the general pathway is unchanged, because the same upstream signal may produce different catalytic output depending on sGC responsiveness. This stage establishes how an extracellular or intercellular chemical signal becomes intracellular second-messenger production.
cGMP formation represents the second-messenger generation stage of the NO–sGC pathway. Once sGC is activated by NO, its catalytic domain converts GTP into cyclic GMP, increasing the concentration of cGMP available to downstream signaling components. The resulting cGMP profile is not determined by formation alone. It reflects the dynamic balance between the rate of synthesis by guanylate cyclase and the rate of degradation by phosphodiesterases, particularly PDE5 in relevant smooth-muscle signaling contexts. Consequently, an identical upstream NO signal can produce different cGMP concentration-time geometries when either sGC catalytic activity or PDE-mediated degradation differs. The formation phase can be characterized by signal amplitude, accumulation rate, temporal persistence, and the transition between rising and declining cGMP concentrations. Sildenafil modifies this balance indirectly by inhibiting PDE5-mediated hydrolysis rather than by directly generating NO or activating sGC. Its effect therefore depends on the presence and dynamics of endogenous NO–sGC signaling that generate cGMP in the first place. Mechanistically, cGMP is the coupling variable connecting upstream NO–sGC activity with downstream PDE5 control and cGMP-dependent smooth-muscle signaling. The cascade is consequently a dynamic balance rather than a one-directional accumulation process.
PDE5 is a cGMP-hydrolyzing phosphodiesterase that contributes to termination and shaping of the cGMP signal. Under baseline pathway operation, PDE5 converts cGMP into non-cyclic products, reducing the concentration available to downstream cGMP-sensitive signaling processes. Sildenafil binds to PDE5 and inhibits its catalytic activity, decreasing the rate of cGMP hydrolysis. The resulting change is best represented as altered cGMP persistence and altered formation-versus-degradation balance rather than direct creation of the second messenger. The magnitude and temporal profile of this modulation depend on the amount of cGMP being generated upstream, PDE5 activity, inhibitor concentration at the molecular target, and the kinetics of association, inhibition, and dissociation. Consequently, PDE5 inhibition can reshape the rising and declining portions of the modeled cGMP signal and modify the concentration–effect relationship downstream. The mechanistic pathway is therefore conditional on upstream NO–sGC activity: PDE5 inhibition changes degradation geometry, while NO and sGC determine the principal source of cGMP formation. This distinction separates sildenafil's molecular action from the upstream trigger and clarifies why PDE5 modulation is one component of a larger interconnected PD cascade. The resulting framework focuses on signaling persistence, not clinical outcomes.
Modeled vasodilation geometry describes the final PD transformation from cGMP signaling into smooth-muscle relaxation. Increased intracellular cGMP activates cGMP-responsive signaling mechanisms, including protein kinase G pathways, which alter calcium handling and contractile machinery and thereby shift the modeled state of smooth-muscle tone toward relaxation. The resulting relationship can be represented as a concentration–effect curve in which cGMP exposure is coupled to a degree of modeled relaxation. Pathway sensitivity influences the position of this curve, while signal amplification and downstream coupling can influence its slope and upper region. Because sildenafil inhibits PDE5 upstream of these downstream events, altered cGMP persistence can change the time-dependent geometry of the modeled relaxation signal. Differences in PDE5 activity, cGMP responsiveness, protein kinase signaling, calcium regulation, or contractile sensitivity can therefore produce different relaxation profiles from similar upstream inputs. In this context, vasodilation differences mean differences in modeled smooth-muscle relaxation geometry, not therapeutic outcomes. The useful mechanistic variables are signal amplitude, concentration–effect coupling, sensitivity, slope, and persistence. This framework treats relaxation as the downstream output of a connected molecular pathway rather than as an isolated property of sildenafil itself.
PD variability can arise at multiple levels of the NO → sGC → cGMP → PDE5 pathway. Potency variability describes shifts in the concentration or signal level associated with a specified modeled effect, reflecting differences in molecular sensitivity and pathway coupling. Slope variability describes changes in how rapidly modeled effect changes as the relevant signaling input changes, producing steeper or shallower concentration–effect geometry. Maximal-effect variability concerns differences in the upper modeled response region when downstream pathway capacity or coupling limits the achievable signal transformation. Pathway-sensitivity variability can originate upstream at NO generation, within sGC activation, during cGMP formation, at PDE5-mediated degradation, or in downstream cGMP-responsive machinery. These stages are coupled, so a change in one domain can propagate through subsequent stages and alter the apparent geometry of the final modeled response. The same sildenafil–PDE5 interaction can therefore be embedded in different pathway states without changing the fundamental molecular mechanism of PDE5 inhibition. A mechanistic PD variability framework consequently separates potency, slope, maximal modeled effect, and pathway sensitivity rather than treating variability as a single parameter. The resulting differences describe signaling-system geometry and responsiveness, not clinical outcomes or recommendations.
NO signaling begins with enzymatic synthesis and release of nitric oxide from cells capable of generating the messenger. Enzymatic production creates NO from an appropriate substrate through nitric oxide synthase activity, after which the molecule can diffuse through nearby biological compartments. Because NO is small, diffusible, and relatively transient, its signaling profile is determined by production rate, release location, diffusion distance, local reaction, and removal. These variables establish the concentration-time geometry encountered by downstream soluble guanylate cyclase. Upstream variability can therefore alter the amplitude, duration, and spatial distribution of the signal entering the NO–cGMP cascade. The pathway does not require NO to remain in a single compartment; instead, diffusion allows the messenger to couple local synthesis with nearby target enzymes. In a mechanistic PD framework, NO availability is therefore the upstream input condition that determines the opportunity for sGC activation. Differences in NO generation or propagation can change downstream cGMP formation even when sGC, PDE5, and other pathway components remain unchanged. The important construct is signal availability and transmission rather than a clinical response. NO signaling thus establishes the initial geometry from which subsequent PD transformations emerge.
NO diffusion geometry determines how the upstream signal reaches soluble guanylate cyclase and therefore how strongly and how long sGC can be activated. Following synthesis and release, NO moves down concentration gradients across short biological distances, while simultaneous reaction and removal constrain its spatial and temporal profile. A localized high-rate source can create a different sGC exposure geometry from a broader or lower-rate source. The relationship is therefore not simply a binary presence-or-absence signal; it includes concentration, duration, spatial reach, and timing. Because sGC responds to NO binding, changes in diffusion geometry can alter the fraction of sGC molecules exposed to activating concentrations and can modify the onset and decline of catalytic activity. These differences propagate into cGMP formation because sGC converts the incoming NO signal into enzymatic production of the second messenger. The resulting cascade behaves as a sequence of coupled transfer functions: NO availability shapes sGC activation, sGC activity shapes cGMP generation, and cGMP availability shapes downstream signaling. In this representation, diffusion is an important upstream determinant of pathway geometry because it connects the location and kinetics of NO synthesis with the molecular target that receives the signal.
| NO Domain | Mechanistic Determinant |
|---|---|
| NO Synthesis | Upstream trigger. |
| NO Diffusion | Signal propagation. |
Soluble guanylate cyclase functions as the principal molecular transducer between NO signaling and cGMP generation. NO binds to the heme-associated regulatory region of sGC, changing the enzyme's conformation and increasing catalytic activity. This conformational transition changes the ability of sGC to convert GTP into cyclic GMP. The magnitude and kinetics of the resulting activation depend on NO availability, binding behavior, enzyme abundance, intrinsic responsiveness, and the duration of the activating signal. Consequently, sGC can be viewed as a signal-conversion stage rather than merely an on-off receptor. Different NO input geometries can produce different catalytic activity profiles, while differences in sGC responsiveness can alter the amount of cGMP generated by a comparable NO signal. The resulting activation profile can include an onset phase, an active interval, and a decline as NO availability and enzyme activation decrease. These features establish the temporal geometry of the second-messenger signal downstream. Mechanistically, sGC therefore determines how efficiently NO is translated into cGMP-producing activity. Its role is distinct from PDE5, which primarily controls cGMP degradation. The two enzymes consequently occupy different positions in the cascade: sGC contributes to formation, while PDE5 contributes to removal and persistence.
cGMP formation geometry emerges from the catalytic activity of sGC and the balance between synthesis and degradation. Activated sGC converts GTP into cGMP, creating a second-messenger signal whose concentration can rise as production exceeds removal. The rate of accumulation depends on sGC activity and substrate availability, while the subsequent profile depends on the competing activity of phosphodiesterases such as PDE5. This creates a dynamic upstream-downstream coupling in which NO controls sGC activation, sGC controls cGMP formation, and PDE5 controls a major component of cGMP hydrolysis. A change at the NO or sGC stage can therefore alter the amount of cGMP available for downstream signaling even if PDE5 activity is unchanged. Conversely, altered PDE5 activity can reshape cGMP persistence without changing the original NO signal. The geometry of the cGMP signal can consequently be described through amplitude, accumulation rate, persistence, and decline. These variables provide the mechanistic bridge between NO input and cGMP-dependent smooth-muscle signaling. Sildenafil acts at the degradation side of this balance through PDE5 inhibition, so its downstream PD effect depends on the cGMP-producing capacity established by the upstream NO–sGC system.
| sGC Domain | Mechanistic Determinant |
|---|---|
| sGC Activation | NO binding. |
| cGMP Formation | Second-messenger geometry. |
PDE5 provides an important degradation pathway for cGMP within the signaling system. Its catalytic activity hydrolyzes cGMP, converting the cyclic second messenger into non-cyclic products and thereby reducing the pool available to activate downstream cGMP-sensitive mechanisms. Sildenafil inhibits PDE5 by binding to the enzyme and reducing its hydrolytic activity. The mechanistic consequence is a shift in the balance between cGMP formation and cGMP degradation. When PDE5 activity is inhibited, cGMP generated by upstream NO–sGC signaling is cleared more slowly, changing its concentration-time profile and increasing its persistence relative to uninhibited degradation. The extent of this change depends on upstream cGMP production, PDE5 abundance and activity, sildenafil–PDE5 interaction kinetics, and the competing activity of other cGMP-regulating processes. PDE5 inhibition therefore does not substitute for NO synthesis or sGC activation; it modifies the downstream handling of the cGMP that those stages produce. This distinction is central to the mechanistic pathway: NO provides the initiating signal, sGC converts that signal into cGMP formation, and PDE5 controls a major route of cGMP removal. Sildenafil changes the degradation term within that coupled system, reshaping the persistence and temporal geometry of the second-messenger signal.
The downstream coupling between PDE5 modulation and modeled vasodilation begins with the altered cGMP concentration profile produced by reduced PDE5 hydrolysis. cGMP interacts with downstream signaling machinery, including cGMP-dependent protein kinase pathways, that regulate components of smooth-muscle contraction such as intracellular calcium handling and contractile-protein activity. A longer-lasting or differently shaped cGMP signal can therefore generate a different modeled relaxation trajectory when downstream sensitivity is held constant. Conversely, changes in downstream sensitivity can produce different modeled relaxation geometries from the same cGMP profile. This means PDE5 inhibition and vasodilation geometry are linked through multiple sequential transformations rather than through a direct one-step relationship. The relevant sequence is PDE5 inhibition, altered cGMP persistence, altered downstream signaling, and then a change in the modeled smooth-muscle relaxation state. The magnitude, slope, and persistence of that final modeled signal depend on both the cGMP profile and downstream pathway responsiveness. Mechanistically, sildenafil's PDE5 interaction is therefore one component of a larger transfer system. The final geometry reflects the combined properties of upstream signal generation, cGMP turnover, and downstream coupling rather than the PDE5 interaction alone.
| PDE5 Domain | Mechanistic Determinant | Link |
|---|---|---|
| PDE5 Inhibition | cGMP persistence. | pde5 pathway |
| Downstream Coupling | Vasodilation geometry. | vasodilation |
Modeled smooth-muscle relaxation is the downstream functional geometry produced by cGMP-dependent signaling. When cGMP increases, it activates cGMP-sensitive effectors, prominently including protein kinase G, which influences intracellular calcium dynamics and components of the contractile apparatus. These molecular changes shift the balance of signals controlling smooth-muscle contraction and relaxation. The resulting relationship can be represented mathematically as a concentration–effect curve connecting a cGMP signal to a modeled degree of relaxation. Curve position reflects sensitivity, while slope describes how rapidly modeled relaxation changes as signaling input changes. The upper region of the curve reflects the modeled capacity of the downstream system under the defined conditions. Because cGMP is generated upstream by NO–sGC signaling and regulated by PDE5-mediated hydrolysis, the relaxation geometry inherits properties from the entire cascade. Sildenafil can therefore alter the temporal cGMP input to the relaxation machinery by inhibiting PDE5, while downstream sensitivity determines how that altered signal is translated into modeled smooth-muscle relaxation. This framework uses vasodilation as a mechanistic output variable. It does not equate modeled relaxation geometry with therapeutic outcomes, subjective effects, or clinical endpoints. The focus remains on molecular signal propagation and the shape of the downstream PD relationship.
Modeled vasodilation differences can arise when any major component of the NO–cGMP pathway differs in its responsiveness or kinetics. Upstream differences in NO generation can alter the initiating signal reaching sGC. Differences in sGC activation can change the conversion of NO into cGMP. Differences in cGMP turnover can change the amplitude and persistence of the second messenger, while downstream changes in protein kinase G signaling, calcium handling, or contractile sensitivity can modify how cGMP is translated into relaxation. These effects can alter several dimensions of modeled vasodilation geometry simultaneously. A shift in sensitivity can move the concentration–effect relationship, a change in coupling can alter its slope, and a limitation in downstream signaling capacity can influence the upper modeled region. Temporal differences can additionally change the duration and decline of the relaxation signal as cGMP concentrations change. Consequently, two pathway states with comparable sildenafil–PDE5 interaction can still produce different modeled relaxation profiles if their upstream or downstream signaling properties differ. Vasodilation geometry is therefore a composite output of pathway responsiveness rather than a direct readout of a single molecular interaction.
| Vasodilation Domain | Mechanistic Determinant | Link |
|---|---|---|
| Relaxation Geometry | cGMP-mediated geometry. | vasodilation |
| Modeled Vasodilation | Downstream geometry. | vasodilation |
Potency variability describes differences in the signaling concentration or molecular input associated with a specified level of modeled effect. Within the NO–cGMP cascade, apparent potency can reflect more than the sildenafil–PDE5 interaction itself because the measured relationship depends on upstream cGMP generation and downstream response sensitivity. Variability in NO availability can alter the amount of cGMP entering the system, while differences in sGC responsiveness can change the conversion of NO into cGMP. PDE5 abundance or activity can further modify the concentration of cGMP remaining available after formation. Downstream sensitivity to cGMP can then shift the modeled concentration–effect relationship independently of upstream events. These coupled determinants can produce a horizontal displacement of modeled response curves without requiring a change in the fundamental mechanism of PDE5 inhibition. Mechanistically, potency is therefore a system-level property emerging from linked pathway sensitivities rather than a fixed characteristic of sildenafil considered in isolation. The same molecular inhibitor can be represented by different apparent potency geometries when NO input, sGC conversion, cGMP turnover, or downstream coupling differs. This framework distinguishes target interaction from the broader PD system in which that interaction operates and avoids treating potency variability as a clinical outcome or recommendation.
Slope and maximal-effect variability describe different dimensions of modeled PD geometry. Slope variability concerns the steepness of the concentration–effect relationship, indicating how strongly modeled effect changes across a defined range of signaling input. A steeper curve implies a more compressed transition between lower and higher modeled effect states, whereas a shallower curve represents a more gradual transition. Maximal-effect variability concerns the upper modeled response region and can arise when downstream pathway capacity, signal amplification, or coupling differs. These properties are mechanistically distinct from potency: two curves can have similar positions but different slopes or upper limits, or can differ in all three dimensions. Within the NO–cGMP cascade, changes in receptor-like sensitivity are represented downstream through cGMP-responsive machinery, while changes in NO–sGC conversion and cGMP turnover modify the signal reaching that machinery. PDE5 inhibition can consequently interact with different underlying pathway geometries and produce different modeled curve shapes. The resulting variability is a property of the coupled signaling network. It should therefore be described using curve position, slope, upper modeled effect, and temporal persistence rather than compressed into a single measure of response.
Pathway-sensitivity variability can occur across every stage of the NO–sGC–cGMP–PDE5 cascade. Upstream variability may change the amount or timing of NO available to activate sGC. At the sGC stage, differences in NO binding or catalytic responsiveness can alter cGMP generation. During cGMP turnover, differences in PDE5 activity can modify the rate of hydrolysis and therefore the persistence of the second messenger. Sildenafil introduces a defined molecular inhibition of PDE5, but the resulting signal geometry remains dependent on the amount of cGMP being generated and the remaining degradation capacity. Downstream, differences in cGMP-sensitive signaling, protein kinase G activity, calcium regulation, and contractile coupling can alter the translation of cGMP into modeled smooth-muscle relaxation. Because these stages operate sequentially, sensitivity differences can propagate forward and become amplified, attenuated, or transformed at later stages. A final modeled PD curve is therefore an integrated representation of multiple transfer functions. Pathway-sensitivity variability should consequently be interpreted as variability in cascade responsiveness rather than as evidence of a different fundamental mechanism. This approach separates molecular action from system-level variation in signal transmission and downstream effect geometry.
| Variability Domain | Mechanistic Determinant | Link |
|---|---|---|
| Potency Variability | Sensitivity variability. | pd variability |
| Slope Variability | Curve geometry variability. | pd variability |
| Pathway-Sensitivity Variability | Cascade responsiveness. | pd variability |
The NO → cGMP cascade represents a sequence of molecular signal transformations linking NO generation with cGMP-dependent smooth-muscle signaling. NO is synthesized enzymatically and released into its local environment, where it diffuses toward soluble guanylate cyclase. NO binding activates sGC through a conformational change, increasing its catalytic conversion of GTP into cGMP. The resulting cGMP signal is regulated by formation and degradation processes, including hydrolysis by PDE5. Sildenafil acts at this degradation stage by inhibiting PDE5, thereby changing the persistence and concentration-time geometry of cGMP. cGMP then activates downstream signaling machinery, including protein kinase G pathways, which influence calcium handling and contractile processes. The final output can be represented as modeled smooth-muscle relaxation geometry with characteristics such as sensitivity, slope, magnitude, and persistence. The cascade is therefore a connected PD signaling model rather than a description of clinical vasodilation. Each stage contributes a transfer function, and variability at one stage can propagate into the geometry of subsequent stages.
NO signaling establishes the upstream input to the cGMP pathway. Nitric oxide is generated enzymatically and released from its source, after which its diffusion, local reaction, and removal determine the concentration-time profile reaching soluble guanylate cyclase. Because NO is transient and diffusible, its signaling geometry includes production rate, release location, spatial reach, and duration. A change in any of these properties can alter the amount and timing of sGC activation. This in turn changes the rate and temporal profile of cGMP formation downstream. Upstream NO variability can therefore propagate through the cascade even when downstream molecular components remain unchanged. The mechanistic relationship is a signal-transfer process: NO availability determines the activating input presented to sGC, sGC converts that input into catalytic activity, and catalytic activity generates cGMP. Differences in NO signaling can consequently shift the amplitude, onset, persistence, or decline of downstream pathway activity. In this framework, NO is not the final response variable; it is the initiating signal whose spatial and temporal geometry helps determine the subsequent PD state.
Soluble guanylate cyclase converts NO signaling into cGMP formation by functioning as an NO-responsive catalytic enzyme. NO binds to the heme-associated regulatory region of sGC and produces a conformational change that increases catalytic activity. Activated sGC then converts GTP into cyclic GMP, generating the second messenger used by downstream signaling pathways. The amount and timing of cGMP formation therefore depend on the NO signal presented to sGC as well as the intrinsic responsiveness and catalytic properties of the enzyme. A stronger or more sustained activating signal can produce a different sGC activity profile from a brief signal, while differences in sGC responsiveness can change cGMP output for a similar NO input. The resulting cGMP concentration-time geometry reflects the balance between synthesis by sGC and degradation by phosphodiesterases. PDE5 contributes importantly to this degradation process, creating a coupling between upstream sGC activation and downstream cGMP persistence. Thus, sGC is the conversion stage that transforms a gaseous NO signal into quantifiable second-messenger production within the signaling cascade.
PDE5 modulation influences modeled vasodilation by changing the degradation rate of cGMP generated through the NO–sGC pathway. PDE5 normally hydrolyzes cGMP, reducing the concentration available to downstream cGMP-sensitive signaling mechanisms. Sildenafil inhibits PDE5 catalytic activity, decreasing this hydrolysis and altering the balance between cGMP formation and removal. The resulting change in cGMP persistence modifies the signal presented to downstream pathways such as protein kinase G signaling, which influences calcium regulation and smooth-muscle contractile machinery. The modeled relaxation response therefore depends on both the altered cGMP profile and the sensitivity of downstream signaling to cGMP. Changes in PDE5 activity can modify the amplitude, persistence, and temporal decline of the cGMP signal, while downstream pathway properties determine how that signal is translated into modeled smooth-muscle relaxation. The relationship is consequently indirect and sequential rather than a direct PDE5-to-relaxation transformation. In mechanistic terms, sildenafil changes one degradation component of a larger signaling network. The resulting vasodilation geometry refers only to modeled smooth-muscle relaxation and concentration–effect behavior, not to therapeutic outcomes or clinical endpoints.
PD variability can arise from differences in signal generation, molecular sensitivity, enzymatic activity, coupling efficiency, and downstream pathway capacity across the NO–sGC–cGMP–PDE5 system. At the upstream stage, differences in NO synthesis, release, diffusion, or local removal can change the signal reaching sGC. At the sGC stage, variation in NO responsiveness or catalytic activity can alter cGMP formation. During cGMP turnover, differences in PDE5 activity can change degradation and signal persistence, while sildenafil-mediated PDE5 inhibition modifies that degradation component. Downstream, differences in cGMP sensitivity, protein kinase G signaling, calcium handling, or contractile coupling can alter modeled smooth-muscle relaxation. These mechanisms can appear as changes in potency, concentration–effect slope, maximal modeled effect, or temporal persistence. Because the pathway is sequential, variability at one stage can propagate into later stages and change the final modeled geometry. PD variability is therefore not necessarily attributable to a single molecular determinant. It can emerge from the combined responsiveness of the entire cascade, with upstream input, intermediate signal conversion, second-messenger turnover, and downstream coupling each contributing distinct dimensions to the final modeled pharmacodynamic profile.